ID   CDN1C_HUMAN             Reviewed;         316 AA.
AC   P49918;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   18-JUN-2025, entry version 203.
DE   RecName: Full=Cyclin-dependent kinase inhibitor 1C;
DE   AltName: Full=Cyclin-dependent kinase inhibitor p57;
DE   AltName: Full=p57Kip2;
GN   Name=CDKN1C; Synonyms=KIP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Embryo;
RX   PubMed=7729684; DOI=10.1101/gad.9.6.650;
RA   Matsuoka S., Edwards M.C., Bai C., Parker S., Zhang P., Baldini A.,
RA   Harper J.W., Elledge S.J.;
RT   "p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor
RT   family, is a candidate tumor suppressor gene.";
RL   Genes Dev. 9:650-662(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8640800;
RA   Reid L.H., Crider-Miller S.J., West A., Lee M.H., Massague J.,
RA   Weissman B.E.;
RT   "Genomic organization of the human p57KIP2 gene and its analysis in the
RT   G401 Wilms' tumor assay.";
RL   Cancer Res. 56:1214-1218(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 12-316, AND VARIANTS.
RX   PubMed=8655143; DOI=10.1007/bf02281873;
RA   Tokino T., Urano T., Furuhata T., Matsushima M., Miyatsu T., Sasaki S.,
RA   Nakamura Y.;
RT   "Characterization of the human p57KIP2 gene: alternative splicing,
RT   insertion/deletion polymorphisms in VNTR sequences in the coding region,
RT   and mutational analysis.";
RL   Hum. Genet. 97:625-631(1996).
RN   [5]
RP   INVOLVEMENT IN BWS.
RX   PubMed=10424811;
RA   Lam W.W.K., Hatada I., Ohishi S., Mukai T., Joyce J.A., Cole T.R.P.,
RA   Donnai D., Reik W., Schofield P.N., Maher E.R.;
RT   "Analysis of germline CDKN1C (p57-KIP2) mutations in familial and sporadic
RT   Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype
RT   correlation.";
RL   J. Med. Genet. 36:518-523(1999).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-268, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INTERACTION WITH PCNA, VARIANTS
RP   IMAGE ASN-274; SER-276; VAL-276; GLU-278 AND PRO-279, AND CHARACTERIZATION
RP   OF VARIANTS IMAGE SER-276 AND GLU-278.
RX   PubMed=22634751; DOI=10.1038/ng.2275;
RA   Arboleda V.A., Lee H., Parnaik R., Fleming A., Banerjee A.,
RA   Ferraz-de-Souza B., Delot E.C., Rodriguez-Fernandez I.A., Braslavsky D.,
RA   Bergada I., Dell'Angelica E.C., Nelson S.F., Martinez-Agosto J.A.,
RA   Achermann J.C., Vilain E.;
RT   "Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome.";
RL   Nat. Genet. 44:788-792(2012).
RN   [8]
RP   VARIANTS BWS LEU-12; PRO-53; ASP-64 DEL; LEU-70; ALA-158 AND PRO-ALA-215
RP   INS, AND PATERNAL IMPRINTING.
RX   PubMed=26077438; DOI=10.1002/humu.22824;
RA   Brioude F., Netchine I., Praz F., Le Jule M., Calmel C., Lacombe D.,
RA   Edery P., Catala M., Odent S., Isidor B., Lyonnet S., Sigaudy S.,
RA   Leheup B., Audebert-Bellanger S., Burglen L., Giuliano F., Alessandri J.L.,
RA   Cormier-Daire V., Laffargue F., Blesson S., Coupier I., Lespinasse J.,
RA   Blanchet P., Boute O., Baumann C., Polak M., Doray B., Verloes A., Viot G.,
RA   Le Bouc Y., Rossignol S.;
RT   "Mutations of the imprinted CDKN1C gene as a cause of the overgrowth
RT   Beckwith-Wiedemann syndrome: clinical spectrum and functional
RT   characterization.";
RL   Hum. Mutat. 36:894-902(2015).
CC   -!- FUNCTION: Potent tight-binding inhibitor of several G1 cyclin/CDK
CC       complexes (cyclin E-CDK2, cyclin D2-CDK4, and cyclin A-CDK2) and, to
CC       lesser extent, of the mitotic cyclin B-CDC2. Negative regulator of cell
CC       proliferation. May play a role in maintenance of the non-proliferative
CC       state throughout life.
CC   -!- SUBUNIT: Interacts with PCNA. {ECO:0000269|PubMed:22634751}.
CC   -!- INTERACTION:
CC       P49918; P11802: CDK4; NbExp=2; IntAct=EBI-519256, EBI-295644;
CC       P49918; Q9NXK8: FBXL12; NbExp=6; IntAct=EBI-519256, EBI-719790;
CC       P49918; P33993: MCM7; NbExp=2; IntAct=EBI-519256, EBI-355924;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P49918-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P49918-2; Sequence=VSP_000867;
CC   -!- TISSUE SPECIFICITY: Expressed in the heart, brain, lung, skeletal
CC       muscle, kidney, pancreas and testis. Expressed in the eye. High levels
CC       are seen in the placenta while low levels are seen in the liver.
CC       {ECO:0000269|PubMed:22634751}.
CC   -!- DEVELOPMENTAL STAGE: Expressed within a subset of cells in the
CC       subcapsular or developing definitive zone of the adrenal gland.
CC       {ECO:0000269|PubMed:22634751}.
CC   -!- DISEASE: Beckwith-Wiedemann syndrome (BWS) [MIM:130650]: A disorder
CC       characterized by anterior abdominal wall defects including exomphalos
CC       (omphalocele), pre- and postnatal overgrowth, and macroglossia.
CC       Additional less frequent complications include specific developmental
CC       defects and a predisposition to embryonal tumors.
CC       {ECO:0000269|PubMed:10424811, ECO:0000269|PubMed:26077438}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Intrauterine growth retardation, metaphyseal dysplasia,
CC       adrenal hypoplasia congenita, and genital anomalies (IMAGE)
CC       [MIM:614732]: A rare condition characterized by intrauterine growth
CC       restriction, metaphyseal dysplasia, congenital adrenal hypoplasia, and
CC       genital anomalies. Patients with this condition may present shortly
CC       after birth with severe adrenal insufficiency, which can be life-
CC       threatening if not recognized early and commenced on steroid
CC       replacement therapy. Other reported features in this condition include,
CC       hypercalciuria and/or hypercalcemia, craniosynostosis, cleft palate,
CC       and scoliosis. {ECO:0000269|PubMed:22634751}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Paternally imprinted, therefore most expression comes
CC       from the maternal allele. {ECO:0000305|PubMed:26077438}.
CC   -!- SIMILARITY: Belongs to the CDI family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U22398; AAA85095.1; -; mRNA.
DR   EMBL; U48869; AAB05896.1; -; Genomic_DNA.
DR   EMBL; BC067842; AAH67842.1; -; mRNA.
DR   EMBL; D64137; BAA11014.1; -; Genomic_DNA.
DR   EMBL; D64137; BAA11015.1; -; Genomic_DNA.
DR   CCDS; CCDS44519.1; -. [P49918-2]
DR   CCDS; CCDS7738.1; -. [P49918-1]
DR   PIR; G02424; G02424.
DR   RefSeq; NP_000067.1; NM_000076.2. [P49918-1]
DR   RefSeq; NP_001116102.1; NM_001122630.2. [P49918-2]
DR   RefSeq; NP_001116103.1; NM_001122631.2. [P49918-2]
DR   RefSeq; NP_001349403.1; NM_001362474.2. [P49918-1]
DR   RefSeq; XP_016872577.1; XM_017017088.1.
DR   AlphaFoldDB; P49918; -.
DR   BioGRID; 107462; 39.
DR   ELM; P49918; -.
DR   FunCoup; P49918; 879.
DR   IntAct; P49918; 17.
DR   MINT; P49918; -.
DR   STRING; 9606.ENSP00000413720; -.
DR   GlyGen; P49918; 1 site.
DR   iPTMnet; P49918; -.
DR   PhosphoSitePlus; P49918; -.
DR   BioMuta; CDKN1C; -.
DR   DMDM; 1705731; -.
DR   jPOST; P49918; -.
DR   MassIVE; P49918; -.
DR   PaxDb; 9606-ENSP00000413720; -.
DR   PeptideAtlas; P49918; -.
DR   ProteomicsDB; 56184; -. [P49918-1]
DR   ProteomicsDB; 56185; -. [P49918-2]
DR   Pumba; P49918; -.
DR   Antibodypedia; 972; 1220 antibodies from 42 providers.
DR   DNASU; 1028; -.
DR   Ensembl; ENST00000414822.8; ENSP00000413720.3; ENSG00000129757.15. [P49918-1]
DR   Ensembl; ENST00000430149.3; ENSP00000411552.2; ENSG00000129757.15. [P49918-1]
DR   Ensembl; ENST00000440480.8; ENSP00000411257.2; ENSG00000129757.15. [P49918-2]
DR   GeneID; 1028; -.
DR   KEGG; hsa:1028; -.
DR   MANE-Select; ENST00000440480.8; ENSP00000411257.2; NM_001122630.2; NP_001116102.1. [P49918-2]
DR   UCSC; uc001lwr.5; human. [P49918-1]
DR   AGR; HGNC:1786; -.
DR   CTD; 1028; -.
DR   DisGeNET; 1028; -.
DR   GeneCards; CDKN1C; -.
DR   GeneReviews; CDKN1C; -.
DR   HGNC; HGNC:1786; CDKN1C.
DR   HPA; ENSG00000129757; Tissue enhanced (brain, ovary).
DR   MalaCards; CDKN1C; -.
DR   MIM; 130650; phenotype.
DR   MIM; 600856; gene.
DR   MIM; 614732; phenotype.
DR   OpenTargets; ENSG00000129757; -.
DR   Orphanet; 231120; Beckwith-Wiedemann syndrome due to CDKN1C mutation.
DR   Orphanet; 85173; IMAGe syndrome.
DR   Orphanet; 436144; Intrauterine growth restriction-short stature-early adult-onset diabetes syndrome.
DR   Orphanet; 397590; Silver-Russell syndrome due to a point mutation.
DR   VEuPathDB; HostDB:ENSG00000129757; -.
DR   eggNOG; KOG4743; Eukaryota.
DR   GeneTree; ENSGT00940000162677; -.
DR   HOGENOM; CLU_077692_0_0_1; -.
DR   InParanoid; P49918; -.
DR   OMA; QENRTDK; -.
DR   OrthoDB; 9940972at2759; -.
DR   PAN-GO; P49918; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; P49918; -.
DR   PathwayCommons; P49918; -.
DR   Reactome; R-HSA-69231; Cyclin D associated events in G1.
DR   Reactome; R-HSA-9661069; Defective binding of RB1 mutants to E2F1,(E2F2, E2F3).
DR   SignaLink; P49918; -.
DR   SIGNOR; P49918; -.
DR   BioGRID-ORCS; 1028; 30 hits in 1178 CRISPR screens.
DR   ChiTaRS; CDKN1C; human.
DR   GeneWiki; Cyclin-dependent_kinase_inhibitor_1C; -.
DR   GenomeRNAi; 1028; -.
DR   Pharos; P49918; Tbio.
DR   PRO; PR:P49918; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P49918; protein.
DR   Bgee; ENSG00000129757; Expressed in placenta and 95 other cell types or tissues.
DR   ExpressionAtlas; P49918; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; IEA:InterPro.
DR   GO; GO:0140678; F:molecular function inhibitor activity; IMP:DisProt.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; IMP:CAFA.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:CAFA.
DR   GO; GO:0030325; P:adrenal gland development; IEA:Ensembl.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0055123; P:digestive system development; IEA:Ensembl.
DR   GO; GO:0060669; P:embryonic placenta morphogenesis; IEA:Ensembl.
DR   GO; GO:0071514; P:genomic imprinting; IEA:Ensembl.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0030099; P:myeloid cell differentiation; IEA:Ensembl.
DR   GO; GO:1904030; P:negative regulation of cyclin-dependent protein kinase activity; IMP:CAFA.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0033673; P:negative regulation of kinase activity; IDA:UniProtKB.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0042326; P:negative regulation of phosphorylation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0042551; P:neuron maturation; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IGI:UniProtKB.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0007096; P:regulation of exit from mitosis; IEA:Ensembl.
DR   GO; GO:1902746; P:regulation of lens fiber cell differentiation; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   DisProt; DP00017; -.
DR   FunFam; 4.10.365.10:FF:000002; cyclin-dependent kinase inhibitor 1C; 1.
DR   Gene3D; 4.10.365.10; p27; 1.
DR   InterPro; IPR003175; CDI_dom.
DR   InterPro; IPR044898; CDI_dom_sf.
DR   PANTHER; PTHR10265; CYCLIN-DEPENDENT KINASE INHIBITOR 1; 1.
DR   PANTHER; PTHR10265:SF44; CYCLIN-DEPENDENT KINASE INHIBITOR 1C; 1.
DR   Pfam; PF02234; CDI; 1.
DR   neXtProt; NX_P49918; -.
DR   PharmGKB; PA26320; -.
DR   TreeFam; TF101111; -.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell cycle; Disease variant; Methylation; Nucleus;
KW   Phosphoprotein; Protein kinase inhibitor; Proteomics identification;
KW   Reference proteome; Repeat; Tumor suppressor.
FT   CHAIN           1..316
FT                   /note="Cyclin-dependent kinase inhibitor 1C"
FT                   /id="PRO_0000190087"
FT   REPEAT          156..159
FT                   /note="1"
FT   REPEAT          160..163
FT                   /note="2"
FT   REPEAT          180..183
FT                   /note="3"
FT   REPEAT          184..187
FT                   /note="4"
FT   REPEAT          188..191
FT                   /note="5"
FT   REPEAT          198..201
FT                   /note="6"
FT   REPEAT          202..205
FT                   /note="7"
FT   REPEAT          206..209
FT                   /note="8"
FT   REPEAT          210..213
FT                   /note="9"
FT   REGION          124..153
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          156..213
FT                   /note="9 X 4 AA repeats of P-A-P-A"
FT   REGION          181..260
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          278..316
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           278..281
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        139..153
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        181..217
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        223..233
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        251..260
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         107
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P49919"
FT   MOD_RES         268
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   VAR_SEQ         1..11
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_000867"
FT   VARIANT         12
FT                   /note="M -> L (in BWS; uncertain significance;
FT                   dbSNP:rs483352966)"
FT                   /evidence="ECO:0000269|PubMed:26077438"
FT                   /id="VAR_075200"
FT   VARIANT         53
FT                   /note="L -> P (in BWS; dbSNP:rs483352968)"
FT                   /evidence="ECO:0000269|PubMed:26077438"
FT                   /id="VAR_075201"
FT   VARIANT         64
FT                   /note="Missing (in BWS; dbSNP:rs483352969)"
FT                   /evidence="ECO:0000269|PubMed:26077438"
FT                   /id="VAR_075202"
FT   VARIANT         70
FT                   /note="P -> L (in BWS; dbSNP:rs483352970)"
FT                   /evidence="ECO:0000269|PubMed:26077438"
FT                   /id="VAR_075203"
FT   VARIANT         158
FT                   /note="P -> A (in BWS; uncertain significance;
FT                   dbSNP:rs483352981)"
FT                   /evidence="ECO:0000269|PubMed:26077438"
FT                   /id="VAR_075204"
FT   VARIANT         171..174
FT                   /note="Missing (in several cancers)"
FT                   /id="VAR_001404"
FT   VARIANT         181..184
FT                   /note="Missing (in hepatocellular carcinomas)"
FT                   /id="VAR_001405"
FT   VARIANT         200..203
FT                   /note="Missing (in a bladder cancer)"
FT                   /id="VAR_001406"
FT   VARIANT         206..209
FT                   /note="Missing (in a breast cancer)"
FT                   /id="VAR_001407"
FT   VARIANT         215
FT                   /note="A -> APA (in BWS; dbSNP:rs772704243)"
FT                   /evidence="ECO:0000269|PubMed:26077438"
FT                   /id="VAR_075205"
FT   VARIANT         274
FT                   /note="D -> N (in IMAGE; dbSNP:rs387907225)"
FT                   /evidence="ECO:0000269|PubMed:22634751"
FT                   /id="VAR_068848"
FT   VARIANT         276
FT                   /note="F -> S (in IMAGE; PCNA binding is disrupted;
FT                   dbSNP:rs387907224)"
FT                   /evidence="ECO:0000269|PubMed:22634751"
FT                   /id="VAR_068849"
FT   VARIANT         276
FT                   /note="F -> V (in IMAGE; dbSNP:rs387907223)"
FT                   /evidence="ECO:0000269|PubMed:22634751"
FT                   /id="VAR_068850"
FT   VARIANT         278
FT                   /note="K -> E (in IMAGE; PCNA binding is disrupted;
FT                   dbSNP:rs387907226)"
FT                   /evidence="ECO:0000269|PubMed:22634751"
FT                   /id="VAR_068851"
FT   VARIANT         279
FT                   /note="R -> P (in IMAGE; dbSNP:rs318240750)"
FT                   /evidence="ECO:0000269|PubMed:22634751"
FT                   /id="VAR_068852"
SQ   SEQUENCE   316 AA;  32177 MW;  A94CCBF09F8CB3E4 CRC64;
     MSDASLRSTS TMERLVARGT FPVLVRTSAC RSLFGPVDHE ELSRELQARL AELNAEDQNR
     WDYDFQQDMP LRGPGRLQWT EVDSDSVPAF YRETVQVGRC RLLLAPRPVA VAVAVSPPLE
     PAAESLDGLE EAPEQLPSVP VPAPASTPPP VPVLAPAPAP APAPVAAPVA APVAVAVLAP
     APAPAPAPAP APAPVAAPAP APAPAPAPAP APAPAPDAAP QESAEQGANQ GQRGQEPLAD
     QLHSGISGRP AAGTAAASAN GAAIKKLSGP LISDFFAKRK RSAPEKSSGD VPAPCPSPSA
     APGVGSVEQT PRKRLR
//
